OÜ PharmaFourRegistered
Key figures
5 080 497 €+23,1%
Revenue 2025
+38,4%
Average annual growth 2019–2025
Ratios
2025−0,6%
Profit margin
0,1%
EBITDA margin
−11,2%
Equity ratio
0,7×
Current ratio
21,6%
Return on equity
692 €
Average gross salary
Balance sheet structure
Current assetsNon-current assetsLiabilitiesEquity
Quarterly figures
| Quarter | Revenue | Number of employees | Labour taxes |
|---|---|---|---|
| Q2 2026 | 1 335 307 € | 24 | 20 327 € |
| Q1 2026 | 1 380 665 € | 21 | 26 754 € |
| Q4 2025 | 1 427 845 € | 13 | 25 329 € |
| Q3 2025 | 1 185 141 € | 13 | 26 744 € |
| Q2 2025 | 1 306 585 € | 13 | 24 164 € |
| Q1 2025 | 1 004 609 € | 12 | 16 570 € |
Source: Tax Board open data — based on VAT returns, may not exactly match revenue in the annual report. Updated quarterly.
Summary of financial statements2019–2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Balance sheet — assets | |||||||
| Total current assets | 235 008 | 792 067 | 714 121 | 859 845 | 869 454 | 750 782 | 957 513 |
| Total non-current assets | 131 252 | 758 194 | 681 495 | 604 040 | 646 557 | 294 250 | 261 250 |
| Total assets | 366 260 | 1 550 261 | 1 395 616 | 1 463 885 | 1 516 011 | 1 045 032 | 1 218 763 |
| Balance sheet — liabilities and equity | |||||||
| Current liabilities | 474 252 | 1 882 460 | 1 562 350 | 1 625 390 | 1 645 188 | 1 152 528 | 1 355 852 |
| Non-current liabilities | — | — | — | — | — | — | — |
| Total liabilities | 474 252 | 1 882 460 | 1 562 350 | 1 625 390 | 1 645 188 | 1 152 528 | 1 355 852 |
| Share capital | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 |
| Retained earnings of previous periods | — | −110 492 | −334 699 | −169 235 | −164 005 | −131 677 | −109 996 |
| Profit for the year | −110 492 | −224 207 | 165 465 | 5230 | 32 328 | 21 681 | −29 593 |
| Total equity | −107 992 | −332 199 | −166 734 | −161 505 | −129 177 | −107 496 | −137 089 |
| Income statement | |||||||
| Sales revenue | 722 365 | 2 767 163 | 3 262 115 | 3 226 907 | 3 364 198 | 4 127 898 | 5 080 497 |
| Operating profit | −102 222 | −212 744 | 176 898 | 16 922 | 44 745 | 23 096 | −29 597 |
| EBITDA | −92 174 | −148 572 | 254 297 | 94 376 | 101 248 | 92 432 | 3403 |
| Profit before income tax | −110 492 | −224 207 | 165 465 | 5230 | 32 328 | 21 681 | −29 593 |
| Profit for the reporting year | −110 492 | −224 207 | 165 465 | 5230 | 32 328 | 21 681 | −29 593 |
| Labour costs | 139 537 | 136 821 | 53 788 | 101 910 | 118 034 | 113 861 | 250 702 |
| Depreciation of non-current assets | 10 048 | 64 172 | 77 399 | 77 454 | 56 503 | 69 336 | 33 000 |
| Other indicators | |||||||
| Employees | 5 | 7 | 1 | 2 | 3 | 3 | 6 |
| Calculated dividend | — | 0 | 0 | 0 | 0 | 0 | 0 |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.
Connections graph
CompanyPersonShareholderOther roleAdditional link
Related companies
Same activity — Ravimite jaemüük